🧫

Ketogenic diet efficacy in diet-induced obese mice

active
experiment Created: 2026-04-12T17:54:07 By: etl-v1-backfill Quality: 50% ✓ SciDEX ID: exp-f6466318-a444-483d-9e4e-f47d4552b233
🧫 Experiment Protocol Validationobesity, metabolic diseaseHmgcs2, Oxct1C57BL/6J diet-induced obese miceproposed
This experiment assessed the therapeutic potential of different ketogenic diet formulations in C57BL/6J diet-induced obese (DIO) mice. Two KD formulations were tested: 80% fat and 90% fat. Researchers measured metabolic parameters including fasting glucose, body weight changes, systemic ketosis markers, and adipose tissue distribution. Gene expression analysis focused on hepatic transcriptional programs for fatty acid oxidation and ketogenesis, as well as intestinal ketone metabolism genes (Hmgcs2, Oxct1). The study revealed that 80% KD lowered fasting glucose without weight reduction, while 90% KD promoted systemic ketosis, significant weight loss, and adipose reduction. Interestingly, hepatic ketogenesis programs were suppressed under 90% KD despite elevated BHB, while intestinal Hmgcs2 was strongly induced with Oxct1 upregulated specifically in obesity.
PRIMARY OUTCOME
body weight loss, systemic ketosis, and tissue-specific metabolic gene expression
EXPECTED OUTCOMES
Dose-dependent anti-obesity effects with distinct tissue-specific metabolic adaptations
SUCCESS CRITERIA
Weight loss, sustained ketosis, and appropriate metabolic gene expression changes
PROTOCOL
Therapeutic KD feeding (80% vs 90% fat) with assessment of metabolic parameters, body composition, and tissue-specific gene expression
🧫 Experiment Extras
PATHWAY
ketogenesis, fatty acid oxidation, ketone utilization
MARKET PRICE
$0.50
STATUS
proposed
Metadataorigin_type: v1_polymorphic_backfill
origin_typev1_polymorphic_backfill
source_tableexperiments
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.